Publications

1. SGLT2 inhibitors for the treatment of type 2 diabetes: relaxing List 2 conditions

   The National Health Care Institute has carried out a substantive assessment of whether the existing list 2 conditions for SGLT2 ...

   Report | 31-07-2018

2. Teduglutide (Revestive®) for the treatment of short bowel syndrome

   The Minister of Health, Welfare and Sport (VWS) has asked the National Health Care Institute to carry out an assessment of ...

   Report | 31-07-2018

3. Obeticholic acid (Ocaliva®) for the treatment of primary biliary cholangitis

   The National Health Care Institute carried out an assessment of whether obeticholic acid (Ocaliva®) is interchangeable with a ...

   Report | 18-07-2018

4. Cariprazine (Reagila®) for the treatment of schizophrenia

   The Minister of Health, Welfare and Sport (WVS) asked the National Health Care Institute  (National Health Care Institute) to ...

   Report | 04-06-2018

5. Dimethyl fumarate (Skilarence®) for the treatment of plaque psoriasis in adults

   The Minister of Health, Welfare and Sport (WVS) asked Zorginstituut Nederland (National Health Care Institute) to carry out an ...

   Report | 09-05-2018

6. Flash Glucose Monitoring (FGM)

   In this report the National Health Care Institute assesses whether Flash Glucose Monitoring (FGM) complies with ‘established ...

   Report | 30-04-2018

7. Rolapitant (Varuby®) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults

   The National Health Care Institute has carried out an assessment of the medicinal product rolapitant (Varuby®). The GVS report ...

   Report | 17-04-2018

8. Belimumab (Benlysta®) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE)

   The National Health Care Institute has carried out an assessment of the medicinal product subcutaneous belimumab (Benlysta®) and ...

   Report | 29-03-2018

9. Fampridine (Fampyra®) in cases of multiple sclerosis (MS)

   The National Health Care Institute carried out an assessment of the medicinal product fampridine (Fampyra®). Based on the ...

   Report | 01-03-2018

10. Nusinersen (Spinraza®) for the treatment of 5q Spinal Muscular Atrophy

    The National Health Care Institute  carried out an assessment on the medicinal product nusinersen (Spinraza®) for the treatment ...

    Report | 07-02-2018